Stoner E
Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey.
J Urol. 1992 May;147(5):1298-302. doi: 10.1016/s0022-5347(17)37547-x.
Finasteride (Proscar--an orally active 5 alpha-reductase enzyme inhibitor) blocks the conversion of testosterone to dihydrotestosterone. The effects of finasteride in patients with benign prostatic hyperplasia were investigated in 2 double-blind, placebo-controlled studies. In study 1, 86 patients were treated with placebo or finasteride (5 to 80 mg. per day) for 12 weeks, followed by a 12-week drug-free period. After 12 weeks of treatment all doses of finasteride showed significant decreases in prostate volume. However, 12 weeks after discontinuation of finasteride prostate volume returned to near baseline values. In study 2, 104 patients were treated with placebo or finasteride (0.2 to 40 mg. per day) for 24 weeks. After 24 weeks of finasteride treatment prostate volume showed a mean decrease of 24% and 28% (p less than 0.01) in the 1 and 5 mg. groups, respectively. Lower doses had a lesser effect on prostate shrinkage. Maximum urinary flow showed a mean increase of 3.7 cc per second when the 1 and 5 mg. groups were combined. Symptom improvement was observed in the 1 and 5 mg. groups, although this was not statistically different from the placebo group due to the small sample size.
非那雄胺（保列治——一种口服活性5α-还原酶抑制剂）可阻断睾酮向双氢睾酮的转化。在两项双盲、安慰剂对照研究中，对非那雄胺治疗良性前列腺增生患者的效果进行了调查。在研究1中，86名患者接受安慰剂或非那雄胺（每日5至80毫克）治疗12周，随后为12周的停药期。治疗12周后，所有剂量的非那雄胺均使前列腺体积显著减小。然而，停用非那雄胺12周后，前列腺体积恢复至接近基线值。在研究2中，104名患者接受安慰剂或非那雄胺（每日0.2至40毫克）治疗24周。非那雄胺治疗24周后，1毫克组和5毫克组的前列腺体积平均分别减小了24%和28%（p<0.01）。较低剂量对前列腺缩小的作用较小。1毫克组和5毫克组合并后，最大尿流率平均每秒增加3.7毫升。1毫克组和5毫克组均观察到症状改善，不过由于样本量小，与安慰剂组相比无统计学差异。
